Clinical Trial Update: A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/Phase 2 study evaluating ZEN003694 in combination with enzalutamide for metastatic castration-resistant prostate cancer has completed, with results po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Enzalutamide (enzalutamide)
• ZEN003694

Snippet

Sponsor: Zenith Epigenetics | Conditions: Metastatic Castration-Resistant Prostate Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-08-10